HCK and bladder transitional cell carcinoma: By simultaneously targeting both HCK and IDO1, DAU intervenes in two pathways, one modulating immune cell phenotype and the other regulating ferroptosis susceptibility, thereby creating a synergistic anti‐tumor effect in BLCA.